Cormorant Asset Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Cormorant Asset Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-893,500	Closed	-$5.89M	–	112
2021 Q2	$5.89M	Sell	893,500 -606,500	-40%	-$4.18M	0.2%	79
2021 Q1	$11M	Buy	+1,500,000	New	+$12.9M	0.24%	70
2020 Q4	–	Sell	-1,000,000	Closed	-$5.94M	–	117
2020 Q3	$5.94M	Sell	1,000,000 -350,000	-26%	-$1.73M	0.23%	71
2020 Q2	$6.95M	Buy	+1,350,000	New	+$8.52M	0.27%	63
2017 Q2	–	Sell	-70,000	Closed	-$413K	–	82
2017 Q1	$413K	Sell	70,000 -38,772	-36%	-$280K	0.06%	70
2016 Q4	$587K	Hold	108,772	–	–	0.08%	69
2016 Q3	$968K	Hold	108,772	–	–	0.11%	71
2016 Q2	$1.04M	Hold	108,772	–	–	0.15%	66
2016 Q1	$1M	Hold	108,772	–	–	0.15%	70
2015 Q4	$1.37M	Sell	108,772 -50,000	-31%	-$594K	0.16%	66
2015 Q3	$1.92M	Hold	158,772	–	–	0.31%	64
2015 Q2	$2.76M	Buy	+158,772	New	+$2.86M	0.37%	54

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Cormorant Asset Management's AVEO Position: Q3 2021 in Review

Cormorant Asset Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2021, closing a stake of 893,500 shares — an estimated $5.89M sold.

Cormorant Asset Management first reported a position in AVEO in Q2 2015 and held it in 12 quarters. The position peaked at $11M in Q1 2021. 52 funds tracked by Wall St. Rank hold AVEO as of Q3 2021.

Cormorant Asset Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Cormorant Asset Management sold 893,500 AVEO Pharmaceuticals, Inc. shares in Q3 2021, an estimated $5.89M.
Cormorant Asset Management first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2015 and held it in 12 quarters.
Cormorant Asset Management's AVEO Pharmaceuticals, Inc. position peaked at $11M in Q1 2021.
52 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2021.

Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.